Healthcare
Phathom Pharmaceuticals, Inc.(PHAT)
Live Price
Offline$10.37
+0.97% today
1Y Change
+16.16%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $950.00M
- Revenue Growth
- +216.9%
- EPS Growth
- +42.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Phathom Pharmaceuticals, Inc. (PHAT) is a Healthcare stock with a market cap of $950.00M and listed on NASDAQ. The stock last traded around $10.37 and up 16.2% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +216.9%, EPS growth of +42.7%, a dividend yield of 0.0%. What stands out right now is revenue +216.9%, EPS +42.7%, free cash flow +37.5% with operating margin -47.1% and ROIC -53.4%. Valuation sits in the middle of the pack at price/sales 4.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PHAT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+216.9% vs +7.6% peer median
Operating Margin
Below sector median
-47.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +216.9% and EPS at +42.7%, with operating margin around -47.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -0.6% | +6.7% | -17.2% |
2026 Feb 26, 2026 | +49.9% | -7.4% | -20.8% | -20.4% |
2025 Oct 30, 2025 | +50.0% | +1.8% | -2.0% | +17.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHAT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PHAT Max Drawdown
-48.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PHAT and SPY.
Company Overview
Phathom Pharmaceuticals, Inc.
NASDAQ Global Select
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
- Leadership
- Steven L. Basta
- IPO Date
- Oct 25, 2019
- Employees
- 427
- Street Address
- 100 Campus Drive
- Mailing
- Florham Park, NJ, 07932
- Region
- Florham Park, NJ, US
- Reporting Currency
- USD
- Investor Line
- 877 742 8466
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.7
- Price/Book
- โ
Growth
- Revenue
- +216.9%
- EPS
- +42.7%
- Free Cash Flow
- +37.5%
Profitability
- Gross Margin
- 84.9%
- Operating Margin
- -47.1%
- Net Margin
- -76.8%
- ROE
- 39.2%
- ROIC
- -53.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.21
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.